ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1695

Ustekinumab Is Effective In Inhibiting Radiographic Progression In Patients With Active Psoriatic Arthritis:  Integrated Data Analysis Of Two Phase 3, Randomized, Placebo-Controlled Studies

Iain B. McInnes1, Christopher T. Ritchlin2, Proton Rahman3, Lluis Puig4, Alice B. Gottlieb5, Michael Song6, Bruce Randazzo6, Shu Li6, Yuhua Wang6, Alan M. Mendelsohn7 and Arthur Kavanaugh8, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4Universitat Autònoma de Barcelona, Barcelona, Spain, 5Tufts Medical Center, Boston, MA, 6Janssen Research & Development, LLC., Spring House, PA, 7Immunology, Janssen Research & Development, LLC., Spring House, PA, 8University of California San Diego, San Diego, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, IL-23 and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ACR Plenary Session II: Discovery 2013

Session Type: Plenary Sessions

Background/Purpose: We describe the effect of ustekinumab (UST), an IL-12/23 p40 inhibitor, on inhibition of progression of structural damage in patients with active psoriatic arthritis (PsA) at wk24 and wk52 in the PSUMMIT 1 and PSUMMIT 2 trials.

Methods: Adult PsA patients with active disease (≥5 SJC and ≥5 TJC; CRP≥0.3mg/dL [ULN 1.0 mg/dL]) despite DMARD and/or NSAID therapy (PSUMMIT 1, n=615; PSUMMIT 2, n=132) or previously treated with DMARD and/or NSAID, and prior anti-TNFα therapy (PSUMMIT 2, n=180) were randomized to UST45mg, 90mg, or PBO at wks 0, 4, and q12wks, thereafter. At wk16, patients with <5% improvement in TJC & SJC entered blinded early escape [EE] (PBO→UST45mg; UST45mg→90mg; 90mg→90mg). No concomitant DMARDs with the exception of MTX (approximately 50% of patients in each study) were permitted.  Radiographs of hands and feet were taken at wks 0, 24, and 52 regardless of EE status, or at the time of study drug discontinuation (unless radiographs were completed within the prior 8wks). Erosions and joint space narrowing (JSN) were evaluated by independent readers blinded to treatment, patient IDs and image time sequence using PsA modified van der Heijde-Sharp (vdH-S) method (total score ranging from 0-528). The major secondary endpoint of change from baseline in total vdH-S scores at wk24 was analyzed based on a pre-specified integrated data analysis using data combined from both studies. Imputation of missing data was done using linear extrapolation or median change of 0.

Results: Baseline disease characteristics including total vdH-S, TJC, SJC and CRP were comparable between PSUMMIT 1 & 2. In the integrated analyses, both UST 45 mg and 90 mg treated patients demonstrated a significant difference in change from baseline in total vdH-S scores at wk24 vs PBO (Table). Moreover, continued inhibition was demonstrated through wk 52; patients randomized to PBO who initiated UST at wk16 or 24 demonstrated slowing of radiographic progression by wk52 (mean change in total vdH-S wk24 to wk52 of 0.08). These observations were reproduced when PSUMMIT 1 was evaluated alone. In PSUMMIT 2, a demonstrable effect of UST on inhibition of structural damage progression could not be discerned; these results may have been impacted by missing radiographic data, especially among PBO-treated patients (23% missing radiographs).

Conclusion: Based upon the pre-specified integrated data analysis, ustekinumab inhibits radiographic progression at wk24.

PSUMMIT 1&2_table.jpg

 


Disclosure:

I. B. McInnes,

Novartis, Janssen Research & Development, LLC.,

8,

UCB,

9;

C. T. Ritchlin,

Amgen, Janssen, UCB, Abbott (AbbVie), Regeneron,

5,

Amgen, Janssen, UCB,

2;

P. Rahman,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

5,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

9;

L. Puig,

Abbvie, Amgen, Janssen, Lilly, Novartis, Pfizer, VBL,

2,

Celgene, Abbvie, Janssen, Novartis, MSO, Pfizer, Lex Pharma,

5;

A. B. Gottlieb,

Janssen, Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia,

2,

Astellas, Janssen, Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs. (Abbvie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Li,

5;

M. Song,

Janssen Research & Development, LLC.,

3;

B. Randazzo,

Janssen Research & Development, LLC.,

3;

S. Li,

Janssen Research & Development, LLC.,

3;

Y. Wang,

Janssen Research & Development, LLC.,

3;

A. M. Mendelsohn,

Janssen Research & Development, LLC.,

3;

A. Kavanaugh,

Janssen Research & Development, LLC.,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ustekinumab-is-effective-in-inhibiting-radiographic-progression-in-patients-with-active-psoriatic-arthritis-integrated-data-analysis-of-two-phase-3-randomized-placebo-controlled-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology